A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910